ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine
WEBSep 5, 2024 · The pooled vaccine effectiveness for prevention of death due to COVID-19 was 93.8% (95% CI 91.5–95.4%), based on five studies. The pooled vaccine effectiveness against asymptomatic SARS-CoV-2 infection was 69.8% (95% CI 60.9–76.7%), based on three studies. 1. Thirty-three publications, which reported data on 31 studies or surveillance ...
Grading of Recommendations, Assessment, Development, and …
WEBSep 9, 2024 · Introduction. On January 31, 2022, the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for Moderna COVID-19 Vaccine (Spikevax) for the prevention of COVID-19 in persons aged ≥18 years 35.As part of the process employed by the Advisory Committee for Immunization Practices (ACIP), a systematic review and Grading of Recommendations, Assessment ...
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAugust 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine ...
WEBSep 6, 2023 · Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants.
Peer-reviewed report on Moderna COVID-19 vaccine publishes
WEBDec 30, 2020 · The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine.
Moderna Achieves Positive Interim Results from Phase 3 Trial of …
WEBMar 26, 2024 · mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222. Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
WEBDec 30, 2020 · The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
WEBJul 14, 2020 · The mRNA-1273 vaccine candidate, manufactured by Moderna, encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a transmembrane anchor and an intact S1–S2 cleavage site.
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded ...
WEBSep 22, 2021 · At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After...
Grading of Recommendations, Assessment, Development, and …
WEBSep 9, 2024 · Articles were included if they provided data on vaccination with the Moderna COVID-19 vaccine and 1) involved human subjects; 2) reported primary data; 3) included adults (ages 18 and older) at risk for SARS-CoV-2 infection; 4) included data relevant to the efficacy and safety outcomes being measured; and 5) included data for the specific ...